Tower Research Capital (TRC)’s AEON Biopharma AEON Stock Holding History

Tower Research Capital (TRC)’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.85K	Buy	2,567 +2,097	+446%	+$1.75K	﹤0.01%	4757
2026 Q1	$463	Buy	+470	New	+$525	﹤0.01%	4866
2025 Q1	–	Sell	-117	Closed	-$4.53K	–	5136
2024 Q4	$4.53K	Buy	117 +44	+60%	+$2.56K	﹤0.01%	4445
2024 Q3	$5.52K	Buy	73 +2	+3%	+$176	﹤0.01%	4258
2024 Q2	$5.36K	Buy	71 +58	+446%	+$13.8K	﹤0.01%	4692
2024 Q1	$11.2K	Buy	13 +12	+1,200%	+$8.69K	﹤0.01%	3592
2023 Q4	$713	Sell	1 -5	-83%	-$2.01K	﹤0.01%	5507
2023 Q3	$2.5K	Buy	+6	New	+$2.75K	﹤0.01%	5140
2022 Q1	–	Sell	-2	Closed	-$2K	–	6050
2021 Q4	$2K	Buy	+2	New	+$1.41K	﹤0.01%	5592

Other funds holding AEON

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s AEON Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its AEON Biopharma (AEON) stake by 446% in Q2 2026, buying an estimated $1.75K and bringing the position to 2,567 shares worth $1.85K. The position accounts for ﹤0.01% of the portfolio, ranked #4757.

Tower Research Capital (TRC) first reported a position in AEON in Q4 2021 and has held it in 9 quarters since. The position peaked at $11.2K in Q1 2024. 22 funds tracked by Wall St. Rank hold AEON as of Q2 2026.

Tower Research Capital (TRC) held 2,567 shares of AEON Biopharma worth $1.85K as of Q2 2026.
Tower Research Capital (TRC) bought 2,097 AEON Biopharma shares in Q2 2026, an estimated $1.75K.
AEON Biopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4757 holding.
Tower Research Capital (TRC) first reported a position in AEON Biopharma in Q4 2021 and has held it in 9 quarters since.
Tower Research Capital (TRC)'s AEON Biopharma position peaked at $11.2K in Q1 2024.
22 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.